

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/619,055
		Filing Date	July 14, 20003
		First Named Inventor	Yann Echelard
		Art Unit	1632
		Examiner Name	Marcia Noble
Sheet 2	of 2	Attorney Docket Number	GTC-208

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MSN		Keefer, CL. et al., Production of Goats After Nuclear Transfer Using Adult Somatic Cells, Vol. 66, no. 1, pgs. 199-203 (2002).	
MSN		Melican, David et al., Effect of Serum Concentration, Method of Trypsinization and Fusion/Activation Utilizing..., vol. 63, no. 6, pgs. 1549-1563 (2005).	
MSN		Behboodi, Esmail, et al., Viable Transgenic Goats Derived From Skin Cells, Vol. 13, No. 3, pgs. 215-224 (2004).	


Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	6	Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Art Unit	1632
				Examiner Name	Marcia Noble
				Attorney Docket Number	GTC-208

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
-----------------------	-----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Group Art Unit	1632
				Examiner Name	Marcia Noble
Sheet	2	of	6	Attorney Docket Number	GTC-208

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MSN		Alberio R, et al., <i>Mammalian Oocyte Activation: Lessons from the Sperm and Implications for Nuclear Transfer</i> , INT J DEV BIOL 2001; 45: 797-809.	
MSN		Arroyo, A. et al., <i>In Vivo Roles Of Integrins During Leukocyte Development And Traffic: Insights From The Analysis Of Mice Chimeric For α_5, α_v, and α_4 Integrins</i> . THE JI 2000;165: 4667-4675.	
MSN		Baguisi A, et al., <i>Production of Goats by Somatic Cell Nuclear Transfer</i> , NAT BIOTECH 1999; 17: 4 56-461.	
MSN		Bondioli K, et al., <i>Production of Identical Bovine Offspring by Nuclear Transfer</i> , THERIOGENOLOGY 1990; 33: 165-174.	
MSN		Byrd, N, et al., <i>Hedgehog Is Required For Murine Yolk Sac Angiogenesis</i> . DEVELOPMENT 2002; 129: 361-372.	
MSN		Cibelli JB, et al., <i>Cloned Transgenic Calves Produced From Nonquiescent Fetal Fibroblasts</i> . SCIENCE 1998; 280: 1256-1258.	
MSN		Gavin, W.G., <i>Gene Transfer Into Goat Embryos</i> , TRANSGENIC ANIMALS – GENERATION AND USE, L. M. Houdebine ed., (Harwood Academic Publishers GmbH., 1996).	
MSN		Helgason, C et al., <i>Targeted Disruption Of SHIP Leads To Hemopoietic Perturbations, Lung Pathology, And A Shortened Life Span</i> . GENES & DEV. 1998; 12: 1610-1620.	

Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
--------------------	-----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Art Unit	1632
				Examiner Name	Marcia Noble
				Attorney Docket Number	GTC-208
Sheet	3	of	6		

MSN		Hu, J.-F, et al., <i>Genomic Deletion Of An Imprint Maintenance Element Abolishes Imprinting Of Both Insulin-Like Growth Factor II And H19</i> . J. BIOL. CHEM. 1997; 272: 20715-20720.	
MSN		Hwang, H.-Y, et al., <i>Creation Of Homozygous Mutants Of Leishmania Donovanii With Single Targeting Constructs</i> . J. BIOL. CHEM. 1996; 271: 30840-30846.	
MSN		Jain, M, et al., <i>Targeted Inactivation Of α_1 Does Not Alter Cardiac Function Or β-Adrenergic Sensitivity</i> . AM. J. PHYSIOL. 2001; 280: 569H-575.	
MSN		Kasinathan P, et al., <i>Effect of Fibroblast Donor Cell Age and Cell Cycle on Development of Bovine Nuclear Transfer Embryos In Vitro</i> , BIOL REPROD. 2001; 64(5): 1487-1493.	
MSN		Kasinathan P, et al., <i>Production of Calves from G1 Fibroblasts</i> , NATURE BIOTECH 2001; 19: 1176-1178.	
MSN		Klug, M, et al., <i>Genetically Selected Cardiomyocytes From Differentiating Embryonic Stem Cells Form Stable Intracardiac Grafts</i> . J. CLIN. INVEST. 1996; 98: 216-224.	
MSN		Koike, H, et al., <i>Efficient Biallelic Mutagenesis With Cre/Loxp-Mediated Inter-Chromosomal Recombination</i> . EMBO REPORTS 2002; 3: 433-437.	
MSN		Kundu, R et al., <i>Targeted Inactivation Of The Coagulation Factor IX Gene Causes Hemophilia B In Mice</i> . BLOOD 1998; 92: 168-174.	
MSN		Lai, L, et al., <i>Feasibility of Producing Porcine Nuclear Transfer Embryos by Using G2/M Stage Fetal Fibroblasts as Donors</i> , BIOL REPROD 2001; 65: 1558-1564.	

Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
---------------------------	-----------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Art Unit	1632
				Examiner Name	Marcia Noble
Sheet	4	of	6	Attorney Docket Number	GTC-208

MSN	Lebel, M, et al., <i>A Deletion Within The Murine Werner Syndrome Helicase Induces Sensitivity To Inhibitors Of Topoisomerase And Loss Of Cellular Proliferative Capacity</i> . PROC. NATL. ACAD. SCI. U.S.A. 1998; 95: 13097-13102.	
MSN	Lim, S, et al., <i>A Shortened Life Span Of EKLF-/- Adult Erythrocytes, Due To A Deficiency Of Beta -Globin Chains, Is Ameliorated By Human Gamma -Globin Chains</i> . BLOOD 1997; 90: 1291-1299.	
MSN	Meng L, et al., <i>Rhesus Monkeys Produced by Nuclear Transfer</i> , BIOL REPROD 1997; 57: 454-459.	
MSN	Mortensen, R, et al., <i>Production Of Homozygous Mutant ES Cells With A Single Targeting Construct</i> . MOL.CELL. BIOL. 1992; 12, 2391-2395.	
MSN	Nagy, A, et al., <i>Targeted Mutagenesis: Analysis Of Phenotype Without Germ Line Transmission</i> . J. CLIN. INVEST. 1996; 97: 1360-1365.	
MSN	Qu, C.-K, et al., <i>Biased Suppression Of Hematopoiesis And Multiple Developmental Defects In Chimeric Mice Containing Shp-2 Mutant Cells</i> . MOL. CELL. BIOL. 1998; 18: 6075-6082.	
MSN	Sakai, E, et al., <i>Recombination And Transcription Of The Endogenous Ig Heavy Chain Locus Is Effected By The Ig Heavy Chain Intronic Enhancer Core Region In The Absence Of The Matrix Attachment Regions</i> . PROC. NATL. ACAD. SCI. U. S. A. 1999; 96: 1526-1531.	
MSN	Saleque, S, et al., <i>The Zinc-Finger Proto-Oncogene Gfi-1b Is Essential For Development Of The Erythroid And Megakaryocytic Lineages</i> . GENES & DEV. 2002; 16: 301-306.	

Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
---------------------------	-----------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Art Unit	1632
				Examiner Name	Marcia Noble
				Attorney Docket Number	GTC-208
Sheet	5	of	6		

MSN	Soudais, C, et al., <i>Targeted Mutagenesis Of The Transcription Factor GATA-4 Gene In Mouse Embryonic Stem Cells Disrupts Visceral Endoderm Differentiation In Vitro</i> . DEVELOPMENT 1995; 121: 3877-3888.	
MSN	Sowell, M et al., <i>Targeted Inactivation Of Alpha 12 Or Alpha 13 Disrupts Activation Of The Cardiac Muscarinic K+ Channel, IK+ACh, In Intact Cells</i> , PROC. NATL. ACAD. SCI. U.S.A. 1997; 94: 7921-7926.	
MSN	Stanford, W, et al., <i>Expression Trapping: Identification Of Novel Genes Expressed In Hematopoietic And Endothelial Lineages By Gene Trapping In ES Cells</i> , BLOOD 1998; 92: 4622-4631.	
MSN	Wall RJ, et al., <i>Transgenic Dairy Cattle: Genetic Engineering on a Large Scale</i> , J DAIRY SCI. 1997; 80(9): 2213-24.	
MSN	Wilmut I, et al., <i>Viable Offspring Derived From Fetal and Adult Mammalian Cells</i> , NATURE 1997; 385: 810-813.	
MSN	Wells DN, et al., <i>Production of Cloned Calves Following Nuclear Transfer with Cultured Adult Mural Granulosa Cells</i> , BIOL REPROD 1999; 60: 996-1005.	
MSN	Wells, et al., <i>Cloning livestock: a return to embryonic stem cells</i> . Trends in Biotechnology. Vol. not known, no. not known, Month, not known, 1-4.	
MSN	Weiss, M and Orkin, S, <i>In Vitro Differentiation Of Murine Embryonic Stem Cells New Approaches To Old Problems</i> . J. CLIN. INVEST. 1996; 97: 591-595.	
MSN	Wu, Q, et al., <i>Generation And Characterization Of Mice Deficient In Hepsin, A Hepatic Transmembrane Serine Protease</i> . J. CLIN. INVEST. 1998; 101: 321-326.	

Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
---------------------------	-----------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Art Unit	1632
				Examiner Name	Marcia Noble
				Attorney Docket Number	GTC-208
Sheet	6	of	6		

MSN	Yang X, et al., <i>Nuclear Totipotency of Cultured Rabbit Morulae to Support Full-Term Development Following Nuclear Transfer</i> , BIOL REPROD 1992; 47: 636-643.	
MSN	Yong Z and L Yuqiang, <i>Nuclear-Cytoplasmic Interaction and Development of Goat Embryos Reconstructed by Nuclear Transplantation: Production of Goats by Serially Cloning Embryos</i> , BIOL REPROD. 1998; 58: 266-269.	
MSN	Zou X, et al., <i>Generation Of Cloned Goats (Capra Hircus) From Transfected Foetal Fibroblast Cells, The Effect Of Donor Cell Cycle</i> , MOL REPROD DEV. 2002; 61: 164-172.	

Examiner Signature	Marcia S. Noble	Date Considered	1-11-06
---------------------------	-----------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.